REHOVOT, Israel and BRIDGEWATER, N.J., March 4, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dov Tamarkin, Chief Executive Officer of Foamix Pharmaceuticals, will provide a corporate overview and business update at the 27 th Annual ROTH Conference.
|Title:||27th Annual ROTH Conference|
|Date:||Monday, March 9|
|Time:||8am Pacific Time.|
|Location:||Ritz Carlton, Dana Point, California|
CONTACT: U.S. Investor Relations Andrew McDonald LifeSci Advisors, LLC 646-597-6987 email@example.com